Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099027 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP1A2CRHR1 | |
| SCHEMBL6097890 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2KDM4EALDH1A1CRHR1 | |
| SCHEMBL6096951 | 0.83 | CYP1A2 (0.56) | SMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL6096679 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP1A2CRHR1 | |
| SCHEMBL6096858 | 0.81 | CYP1A2 (0.64) | SMN1; SMN2CYP1A2ALDH1A1CYP3A4TSHR | |
| SCHEMBL6097821 | 0.79 | CYP1A2 (0.81) | SMN1; SMN2CYP1A2MAOB | |
| SCHEMBL6095060 | 0.79 | CYP1A2 (0.61) | CYP1A2ALDH1A1MAOB | |
| SCHEMBL6096828 | 0.79 | CYP1A2 (0.60) | SMN1; SMN2CYP1A2KDM4EALDH1A1NFKB1 | |
| SCHEMBL6097347 | 0.78 | CYP1A2 (0.63) | SMN1; SMN2CYP1A2MAOB | |
| SCHEMBL6096794 | 0.78 | CYP1A2 (0.56) | SMN1; SMN2CYP1A2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | SMN1; SMN2 4491/4885CYP1A2 670/4885KDM4E 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.